LATANOPROST OPHTHALMIC SOLUTION 0.005% vs TIMOLOL MALEATE

Compare LATANOPROST OPHTHALMIC SOLUTION 0.005% (IYUZEH) and TIMOLOL MALEATE (Timolol Maleate) — clinical data, side effects, and patient experiences.

LATANOPROST OPHTHALMIC SOLUTION 0.005%

IYUZEH · Glaucoma Agent

How it works

12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man sugg...

Approved for

See full prescribing information

OphthalmicTablet

TIMOLOL MALEATE

Timolol Maleate · Glaucoma Agent

How it works

Other agent

Approved for

benzalkonium chloride

or when use of a preservative-free topical medication is advisable.

OphthalmicTablet

Quick Comparison

LATANOPROST OPHTHALMIC SOLUTION 0.005%TIMOLOL MALEATE

Drug Class

Glaucoma Agent

Route

Ophthalmic

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LATANOPROST OPHTHALMIC SOLUTION 0.005%

Drug Not Working

>10%

Fatigue

1-10%

Headache

1-10%

Shortness of Breath

1-10%

Blurred Vision

1-10%

Dizziness

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

TIMOLOL MALEATE

Drug Not Working

1-10%

Fatigue

1-10%

Blurred Vision

1-10%

Dizziness

1-10%

Diarrhea

0.1-1%

Shortness of Breath

0.1-1%

Headache

0.1-1%

Nausea

0.1-1%

FDA Warnings

LATANOPROST OPHTHALMIC SOLUTION 0.005%

5 WARNINGS AND PRECAUTIONS Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur
IYUZEH should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

TIMOLOL MALEATE

WARNINGS As with many topically applied ophthalmic drugs, this drug is absorbed systemically
For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate (see CONTRAINDICATIONS )
, chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which Timolol Maleate Ophthalmic Solution in OCUDOSE is contraindicated [see CONTRAINDICATIONS ]) should, in general, not receive beta-blockers, including Preservative-free Timolol Maleate Ophthalmic Solution in OCUDOSE
This may augment the risk of general anesthesia in surgical procedures

Clinical Trial Data

No head-to-head clinical studies found for LATANOPROST OPHTHALMIC SOLUTION 0.005% vs TIMOLOL MALEATE.

LATANOPROST OPHTHALMIC SOLUTION 0.005% vs TIMOLOL MALEATE: What You Should Know

Key Differences

Both LATANOPROST OPHTHALMIC SOLUTION 0.005% and TIMOLOL MALEATE belong to the Glaucoma Agent class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

LATANOPROST OPHTHALMIC SOLUTION 0.005% carries 2 FDA warnings. TIMOLOL MALEATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

TIMOLOL MALEATE vs TRAVOPROST OPHTHALMIC SOLUTION→DORZOLAMIDE HYDROCHLORIDE vs TIMOLOL MALEATE→DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION vs TIMOLOL MALEATE→LATANOPROST OPHTHALMIC SOLUTION vs TIMOLOL MALEATE→TIMOLOL MALEATE vs TRAVOPROST→BRIMONIDINE TARTRATE vs TIMOLOL MALEATE→

Loading comparison data...

LATANOPROST OPHTHALMIC SOLUTION 0.005% vs TIMOLOL MALEATE

Compare LATANOPROST OPHTHALMIC SOLUTION 0.005% (IYUZEH) and TIMOLOL MALEATE (Timolol Maleate) — clinical data, side effects, and patient experiences.

LATANOPROST OPHTHALMIC SOLUTION 0.005%

IYUZEH · Glaucoma Agent

How it works

12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man sugg...

Approved for

See full prescribing information

OphthalmicTablet

TIMOLOL MALEATE

Timolol Maleate · Glaucoma Agent

How it works

Other agent

Approved for

benzalkonium chloride

or when use of a preservative-free topical medication is advisable.

OphthalmicTablet

Quick Comparison

LATANOPROST OPHTHALMIC SOLUTION 0.005%TIMOLOL MALEATE

Drug Class

Glaucoma Agent

Route

Ophthalmic

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LATANOPROST OPHTHALMIC SOLUTION 0.005%

Drug Not Working

>10%

Fatigue

1-10%

Headache

1-10%

Shortness of Breath

1-10%

Blurred Vision

1-10%

Dizziness

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

TIMOLOL MALEATE

Drug Not Working

1-10%

Fatigue

1-10%

Blurred Vision

1-10%

Dizziness

1-10%

Diarrhea

0.1-1%

Shortness of Breath

0.1-1%

Headache

0.1-1%

Nausea

0.1-1%

FDA Warnings

LATANOPROST OPHTHALMIC SOLUTION 0.005%

5 WARNINGS AND PRECAUTIONS Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur
IYUZEH should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

TIMOLOL MALEATE

WARNINGS As with many topically applied ophthalmic drugs, this drug is absorbed systemically
For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate (see CONTRAINDICATIONS )
, chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which Timolol Maleate Ophthalmic Solution in OCUDOSE is contraindicated [see CONTRAINDICATIONS ]) should, in general, not receive beta-blockers, including Preservative-free Timolol Maleate Ophthalmic Solution in OCUDOSE
This may augment the risk of general anesthesia in surgical procedures

Clinical Trial Data

No head-to-head clinical studies found for LATANOPROST OPHTHALMIC SOLUTION 0.005% vs TIMOLOL MALEATE.

LATANOPROST OPHTHALMIC SOLUTION 0.005% vs TIMOLOL MALEATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.